Monoclonal antibody · Antagonist of PD-1 (PDCD1) · developed by Agenus
Balstilimab is a monoclonal antibody that binds to PD-1 on T cells, blocking its interaction with PD-L1 and restoring immune function through T-cell activation. It is studied in multiple solid tumors including colorectal, gastric, breast, cervical, and pancreatic cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06279130 | Phase 2/3 | Resectable MMR-deficient Solid Tumors | Recruiting | AGEN |
| NCT04943627 | Phase 3 | Advanced Cancer | Withdrawn | AGEN |
| NCT05318469 | Phase 1/2 | Anatomic Stage IV Breast Cancer AJCC v8 | Recruiting | AGEN |
| NCT05205330 | Phase 1/2 | Refractory Metastatic Colorectal Cancer | Active not recruiting | AGEN |
| NCT05033132 | Phase 2 | Cervical Cancer | Withdrawn | AGEN |
| NCT06095674 | Phase 1 | Cervical Cancer | Unknown | AGEN |
| NCT06751524 | N/A | Colorectal Cancer (CRC) | Available | AGEN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Anatomic Stage IV Breast Cancer AJCC v8Gastric CancerMetastatic GI CancersMetastatic Microsatellite-stable Colorectal CancerMetastatic Triple-Negative Breast CarcinomaMismatch Repair Protein ProficientRefractory Metastatic Colorectal CancerResectable MMR-deficient Solid TumorsResectable MMR-proficient Solid TumorsSolid TumorAdvanced CancerCervical CancerColorectal Cancer (CRC)Hepatocellular Carcinoma (HCC)
Updated Oct 3, 2026. Something wrong or missing? Report it on the AGEN page.
See AGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AGEN catalysts and pipeline →